Dr. Dupont is a renowned expert in the fields of cell therapy and oncology, with long-standing and deep experience in developing therapies and programs dedicated to addressing high unmet medical needs. Dr. Dupont serves as Global Head of Research & Development (R&D) including Medical and Regulatory Affairs. Prior to joining Atara, he served as the Chief Medical Officer at Gossamer Bio, overseeing global development, regulatory, and quality activities for the company, and advancing therapeutics in the disease areas of immunology, inflammation, and oncology. Dr. Dupont is committed to bringing transformative therapies to patients.
Prior to his role at Gossamer Bio, he served as Vice President and Global Head of Breast and Gynecologic Cancer Development for Genentech/Roche, where he was responsible for the global development of Herceptin® (trastuzumab), Perjeta® (pertuzumab), Kadcyla® (ado-trastuzumab emtansine), and Tecentriq® (atezolizumab), among others. Prior to that, Dr. Dupont was Chief Medical Officer and Senior Vice President of OncoMed Pharmaceuticals, Inc., where he oversaw the successful submissions of eight investigational new drug applications (INDs) and 26 clinical trial initiations.
Dr. Dupont has been involved in tumor immunology research and clinical investigations for more than 25 years, ranging from cellular therapy to tumor vaccine therapy and immune checkpoints. Dr. Dupont has received numerous grants and awards, and has co-authored 47 peer-reviewed publications, has 30 patents, and has also served as a faculty member and laboratory researcher at Memorial Sloan Kettering Cancer Center (MSK) and adjunct clinical faculty in medical oncology at Stanford University.
Dr. Dupont received his M.D. from the Joan & Sanford I. Weill Medical College of Cornell University, his M.A. in philosophy from New York University, and his undergraduate degree in philosophy from Vassar College. He also served as Assistant Chief Resident and completed his Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center (MSK), his Internal Medicine Residency at the New-York Presbyterian Hospital — Cornell Campus, and his Internal Medicine Internship at The University of Michigan Medical Center.
Jakob and his family live in the Bay Area and enjoy outdoor activities including skiing, tennis, and canoe camping. Jakob is also an avid cook, gardener, and soccer fan.
What is Jakob Dupont's net worth?
The estimated net worth of Jakob Dupont is at least $201,142.21 as of March 2nd, 2023. Dr. Dupont owns 290,794 shares of Atara Biotherapeutics stock worth more than $201,142 as of April 18th. This net worth estimate does not reflect any other assets that Dr. Dupont may own. Learn More about Jakob Dupont's net worth.
How do I contact Jakob Dupont?
Has Jakob Dupont been buying or selling shares of Atara Biotherapeutics?
Jakob Dupont has not been actively trading shares of Atara Biotherapeutics during the last quarter. Most recently, Jakob Dupont sold 5,074 shares of the business's stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $3.63, for a transaction totalling $18,418.62. Following the completion of the sale, the executive vice president now directly owns 290,794 shares of the company's stock, valued at $1,055,582.22. Learn More on Jakob Dupont's trading history.
Who are Atara Biotherapeutics' active insiders?
Are insiders buying or selling shares of Atara Biotherapeutics?
During the last year, Atara Biotherapeutics insiders bought shares 2 times. They purchased a total of 279,020 shares worth more than $64,384.40. During the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 184,801 shares worth more than $237,993.35. The most recent insider tranaction occured on March, 4th when CEO Pascal Touchon sold 24,844 shares worth more than $17,887.68. Insiders at Atara Biotherapeutics own 4.5% of the company.
Learn More about insider trades at Atara Biotherapeutics. Information on this page was last updated on 3/4/2024.
